6/4/2021

speaker
Operator
Conference Operator

Hi, and welcome to the Surface Oncology Clinical Update for SRF388 and SRF617. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone. Please be advised that today's conference may be recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Jessica Fees, Chief Financial Officer at Surface Oncology. Please go ahead.

speaker
Jessica Fees
Chief Financial Officer

Thank you for joining today's clinical study update webcast. My name is Jessica Fees, and I am the Chief Financial Officer at Surface Oncology. With me on the webcast are Rob Ross, Chief Executive Officer, and Allison O'Neill, Chief Medical Officer. Please note that this call is being webcast live and will be archived on the Investors and Media section of the Surface Oncology website. Before we begin, a few forward-looking statements. This presentation has been prepared by Surface Oncology and includes certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. The statements made in this presentation speak only as of the date hereof, and any forward-looking statements contained herein are based on assumptions that surface oncology believes to be reasonable as of this date. Surface oncology undertakes no obligation to update these statements as a result of new information or future events. I now turn the call over to Rob.

speaker
Rob Ross
Chief Executive Officer

Thank you, and welcome, everyone. We are very pleased to be able to share today clinical updates on both our lead clinical programs, SRF388, and SRF617. Both are immuno-oncology antibodies directed at novel targets meant to activate the immune system to kill tumor cells and ultimately help patients. We are proud of the fact that, to our knowledge, we are the first to present clinical data on molecules targeting either IL-27 or CD39. The headline today, is that with SRF388, our anti-IL27 antibody, we have seen clear evidence of monotherapy activity in the form of a confirmed partial response in a patient with highly treatment refractory lung cancer. With any first-in-class agent in immuno-oncology, it can be a struggle to prove that the pathway you are targeting actually matters in people with cancer. Here we have clear evidence that, at least for this patient, not only does IL27 matter, but if you inhibited IL-27 by itself, that is enough to stimulate a significant anti-tumor response. Moreover, the drug is well-tolerated, the recommended Phase II dose has been selected, and expansion cohorts are actively enrolling. We can also announce today that we have entered into a clinical agreement with Roche to begin a trial in first-line advanced liver cancer, combining SRF388 with atezolizumab and bevacizumab, the standard of care for these patients. SRF617, our anti-CD39 antibody, has been similarly well tolerated, and we are currently at dose levels that we expect are biologically active. We have opened our combination arms in that trial and, to date, have seen a partial response in a patient with second-line pancreatic cancer treated with SRF617 along with chemotherapy. Without further delay, I'll let Allison O'Neill, our chief medical officer, walk you through the details of the clinical data on both programs. Allison? Thank you, Rob, and good morning, everyone.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-